Stock 9969 INNOCARE PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:42 28/06/2024 pm IST 		5-day change 1st Jan Change
4.82 HKD +3.66% Intraday chart for InnoCare Pharma Limited +1.47% -30.04%
21/06 China Grants Priority Review Status for InnoCare's Lymphoma Drug; Shares Jump 6% MT
20/06 InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14,626 18,696 21,794 12,432 8,858 - -
Enterprise Value (EV) 1 11,830 14,035 14,349 5,556 -907.9 -3,216 -5,882
P/E ratio -23.6 x -249 x -20.1 x -16.9 x -9.82 x -12.7 x -31.6 x
Yield - - - - - - -
Capitalization / Revenue 10,723 x 17.9 x 34.8 x 16.8 x 9.99 x 7.03 x 5.05 x
EV / Revenue 8,673 x 13.5 x 22.9 x 7.52 x -1.02 x -2.55 x -3.35 x
EV / EBITDA -21.6 x -93.6 x -20 x -9.13 x 1.06 x 5.09 x 13.3 x
EV / FCF -27.9 x 9,815 x -17.8 x -6 x 1.37 x 14.5 x 77.1 x
FCF Yield -3.58% 0.01% -5.61% -16.7% 73.3% 6.89% 1.3%
Price to Book 3.54 x 3.34 x 2.8 x 1.54 x 1.44 x 1.45 x 1.57 x
Nbr of stocks (in thousands) 12,89,165 14,99,673 17,64,321 17,63,130 17,60,932 - -
Reference price 2 11.35 12.47 12.05 6.262 4.486 4.486 4.486
Announcement Date 26/03/21 22/03/22 27/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1.247 1.364 1,043 625.4 738.5 886.8 1,260 1,754
EBITDA 1 - -547.5 -150 -715.8 -608.9 -855.2 -631.8 -440.7
EBIT 1 - -559 -182.5 -777.3 -701.5 -873 -726.8 -512.8
Operating Margin - -40,981.38% -17.5% -124.29% -94.98% -98.44% -57.68% -29.23%
Earnings before Tax (EBT) 1 - -464.3 -20.12 -893.7 -644.2 -742 -601.8 -313.4
Net income 1 - -463.8 -64.54 -886.6 -631.3 -724.9 -591.8 -311.3
Net margin - -34,002.42% -6.19% -141.76% -85.47% -81.74% -46.97% -17.75%
EPS 2 -9.320 -0.4800 -0.0500 -0.6000 -0.3700 -0.4570 -0.3522 -0.1418
Free Cash Flow 1 - -423.5 1.43 -804.5 -926 -665 -221.7 -76.31
FCF margin - -31,049.41% 0.14% -128.64% -125.38% -74.99% -17.59% -4.35%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 18/03/20 26/03/21 22/03/22 27/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 S1 2025 S2
Net sales 1 0.748 0.616 101.7 941.4 246 195.7 183.8 379.4 - 159.8 201.2 361 165.8 196.3 362.1 216 261.3 477.3 236.6 482.9 724.3
EBITDA - - - - - - - - - - - - - - - - - - - - -
EBIT 1 - - -212.2 - -354.9 -397.6 -232.6 -379.7 - - -186.3 -366.3 - -232.7 -403.9 -208.6 -226.6 -435.3 - - -
Operating Margin - - -208.76% - -144.28% -203.24% -126.57% -100.06% - - -92.6% -101.48% - -118.58% -111.55% -96.58% -86.72% -91.19% - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - - - - - - - - -
EPS - - -0.1600 0.1100 -0.3100 - - -0.2900 -0.2500 -0.0600 - -0.1200 - - -0.2100 - - -0.2500 - - -
Dividend per Share - - - - - - - - - - - - - - - - - - - - -
Announcement Date 21/08/20 26/03/21 27/08/21 22/03/22 21/08/22 13/11/22 27/03/23 27/03/23 29/08/23 13/11/23 28/03/24 28/03/24 13/05/24 - - - - - - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 2,796 4,660 7,445 6,875 9,766 12,075 14,741
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -424 1.43 -805 -926 -665 -222 -76.3
ROE (net income / shareholders' equity) - - -1.14% -13.4% -8.56% -13.3% -11.5% -8.67%
ROA (Net income/ Total Assets) - -13% -1.08% -10% -6.24% -7.7% -7.7% -5.8%
Assets 1 - 3,577 5,976 8,860 10,120 9,414 7,685 5,368
Book Value Per Share 2 - 3.210 3.740 4.310 4.050 3.120 3.090 2.860
Cash Flow per Share 2 - -0.2200 0.0900 -0.3800 -0.4000 -0.1900 - -
Capex 1 - 251 166 239 255 45.8 110 130
Capex / Sales - 18,401.39% 15.88% 38.21% 34.48% 5.16% 8.75% 7.43%
Announcement Date 18/03/20 26/03/21 22/03/22 27/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for InnoCare Pharma Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.486 CNY
Average target price
9.32 CNY
Spread / Average Target
+107.77%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INNOCARE PHARMA LIMITED Stock InnoCare Pharma Limited
-30.04% 1.22B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9969 Stock
  4. Financials InnoCare Pharma Limited